Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
42.44
+2.74 (6.90%)
Nov 20, 2024, 4:00 PM EST - Market closed
Harrow Revenue
Harrow had revenue of $49.26M in the quarter ending September 30, 2024, with 43.75% growth. This brings the company's revenue in the last twelve months to $169.14M, up 48.15% year-over-year. In the year 2023, Harrow had annual revenue of $130.19M with 46.95% growth.
Revenue (ttm)
$169.14M
Revenue Growth
+48.15%
P/S Ratio
8.92
Revenue / Employee
$536,946
Employees
315
Market Cap
1.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teladoc Health | 2.59B |
U.S. Physical Therapy | 639.06M |
Alphatec Holdings | 572.74M |
InMode | 423.75M |
BioCryst Pharmaceuticals | 412.58M |
Kiniksa Pharmaceuticals International, | 384.10M |
Certara | 372.80M |
Schrödinger | 193.35M |
HROW News
- 3 hours ago - Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. - Business Wire
- 6 days ago - Harrow Announces Participation in Upcoming Investor Conferences - Business Wire
- 6 days ago - Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Harrow Announces Third Quarter 2024 Financial Results - Business Wire
- 8 days ago - Harrow Launches Access and Affordability Program with Price Reductions for Branded Products - Business Wire
- 9 days ago - Harrow Announces Market Access Wins for VEVYE® - Business Wire
- 10 days ago - Harrow: VEVYE And Its Impact On The DED Market - Seeking Alpha
- 14 days ago - Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products - Business Wire